Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “RCT2100 supplied at varying dose strengths. Co- administered via oral inhalation using nebulizer for 4 weeks with ivacaftor after initial 2 weeks of ivacaftor dosing run in period”In the company’s words, NCT06237335 on ClinicalTrials.gov
- Tested for
- Cystic Fibrosis
- Main trialPhase 2
- “This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.”In the company’s words, NCT06237335 on ClinicalTrials.gov
Other drugs for Cystic Fibrosis
- ELX/TEZ/IVAVertex Pharmaceuticals · Phase 3
- IvacaftorVertex Pharmaceuticals · Phase 3
- VNZ/TEZ/D-IVAVertex Pharmaceuticals · Phase 3
- SP-101Spirovant Sciences, Inc. · Phase 1/2
- 4D-7104D Molecular Therapeutics · Phase 2
- ARCT-032Arcturus Therapeutics, Inc. · Phase 2
Coming up1
- NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Nov 2026 | A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026